Despite facing much public scrutiny for rushing the Sputnik V vaccine, the efficacy of Russia’s vaccine has been validated in a peer-reviewed study that was published in The Lancet. The Lancet published an interim analysis of Phase III data that Sputnik V has demonstrated an efficacy rate against the original strain of COVID-19 of 91.6%. From the cases analyzed, Russia’s government confirmed that over 98% of volunteers had a humoral immune response and 100% developed cell immune response.
Read more here.
More on: News Regulatory